

# Michael E Weinblatt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/103206/publications.pdf>

Version: 2024-02-01

170  
papers

19,815  
citations

20817  
60  
h-index

10445  
139  
g-index

185  
all docs

185  
docs citations

185  
times ranked

11770  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of Shared Epitope in Rheumatoid Arthritis Prognosis in Relation to Anti-Citrullinated Protein Antibody Positivity. <i>Rheumatology and Therapy</i> , 2022, 9, 637-647.	2.3	4
2	Screening for preclinical parenchymal lung disease in rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 3234-3245.	1.9	14
3	Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2022, 9, 391-409.	2.3	3
4	Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry. <i>Arthritis Care and Research</i> , 2021, 73, 471-480.	3.4	12
5	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. <i>Arthritis and Rheumatology</i> , 2021, 73, e1-e12.	5.6	201
6	Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR). <i>Journal of Rheumatology</i> , 2021, 48, 767-774.	2.0	33
7	Systematic review of recommendations on the use of methotrexate in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 1259-1271.	2.2	11
8	Treatment of Severe Multicentric Reticulohistiocytosis With Upadacitinib. <i>JAMA Dermatology</i> , 2021, 157, 735.	4.1	6
9	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 924-939.	3.4	466
10	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1108-1123.	5.6	339
11	Perceptions and Challenges Experienced by African Physicians When Prescribing Methotrexate for Rheumatic Disease: An Exploratory Study. <i>ACR Open Rheumatology</i> , 2021, 3, 522-530.	2.1	4
12	Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. <i>Blood Advances</i> , 2021, 5, 3445-3456.	5.2	22
13	Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies. <i>Arthritis Research and Therapy</i> , 2021, 23, 1.	3.5	41
14	Dr. Kremer et al reply. <i>Journal of Rheumatology</i> , 2021, , jrheum.210992.	2.0	0
15	Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, and Medication Change. <i>Journal of Rheumatology</i> , 2020, 47, 333-340.	2.0	5
16	Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs: Results From a Real-World Study. <i>Arthritis Care and Research</i> , 2020, 72, 176-183.	3.4	11
17	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 88-93.	0.9	63
18	Georgia Abortion Law and Our Commitment to Patients. <i>Arthritis and Rheumatology</i> , 2020, 72, 377-378.	5.6	1

#	ARTICLE	IF	CITATIONS
19	Rheumatoid arthritis-related lung disease detected on clinical chest computed tomography imaging: Prevalence, risk factors, and impact on mortality. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1216-1225.	3.4	18
20	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2. <i>Arthritis and Rheumatology</i> , 2020, 72, e1-e12.	5.6	64
21	Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 188.	3.5	2
22	The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for Achievement of Treatment Strategies. <i>Journal of Rheumatology</i> , 2020, 48, jrheum.200692.	2.0	9
23	Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center's Experience With 400 Patients. <i>ACR Open Rheumatology</i> , 2020, 2, 357-361.	2.1	43
24	Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001096.	3.8	3
25	Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2017.	2.4	0
26	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. <i>Arthritis and Rheumatology</i> , 2020, 72, 1241-1251.	5.6	142
27	Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry. <i>Clinical Rheumatology</i> , 2019, 38, 3401-3412.	2.2	11
28	The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.2	5
29	Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE). <i>Rheumatology and Therapy</i> , 2019, 6, 559-571.	2.3	15
30	Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1042-1055.	5.6	135
31	Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis. <i>Practical Laboratory Medicine</i> , 2019, 16, e00122.	1.3	2
32	Association of Changes in Anticitrullinated Protein Antibody Levels With Resource Use and Disease Activity Measures in Rheumatoid Arthritis Patients aÂUS Observational Cohort. <i>Clinical Therapeutics</i> , 2019, 41, 1057-1065.e3.	2.5	0
33	Rheumatoid Nodule Formation in the Kidney: A Diagnosis of Exclusion and a Rare Manifestation of Rheumatoid Arthritis Involving the Kidney. <i>Kidney International Reports</i> , 2019, 4, 745-748.	0.8	2
34	Prevalence and predictors for sustained remission in rheumatoid arthritis. <i>PLoS ONE</i> , 2019, 14, e0214981.	2.5	12
35	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for <i>CD40</i> and CD39. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1055-1061.	0.9	25
36	Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis. <i>BMC Rheumatology</i> , 2019, 3, 3.	1.6	18

#	ARTICLE	IF	CITATIONS
37	Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1285-1286.	0.9	5
38	Incidence and Predictors of Dyspnea on Exertion in a Prospective Cohort of Patients With Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2019, 1, 4-15.	2.1	5
39	AB0373â€¦A COMPARATIVE EFFECTIVENESS STUDY OF ABATACEPT AND TNFI AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS USING REAL-WORLD DATA. , 2019, , .		0
40	SAT0072â€¦EVALUATION OF RHEUMATOID ARTHRITIS TREATMENTS AND JOINT OUTCOMES IN RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE. , 2019, , .		0
41	FRI0171â€¦CLINICAL RESPONSES IN PATIENTS WITH INADEQUATE RESPONSE TO BDMARDS UPON TREATMENT WITH UPADACITINIB. , 2019, , .		3
42	THU0065â€¦VALIDATION OF THE ADJUSTED MULTI-BIOMARKER DISEASE ACTIVITY SCORE FOR PREDICTING RISK OF RADIOGRAPHIC PROGRESSION FOR PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
43	SAT0162â€¦A POOLED ANALYSIS OF 1-YEAR CLINICAL OUTCOMES AMONG 6-MONTH RESPONDERS AND NON-RESPONDERS FROM THREE RANDOMISED CONTROLLED STUDIES OF TNF INHIBITOR BIOSIMILARS IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
44	THU0102â€¦PATIENT DISEASE TRAJECTORIES IN BARICITINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE. , 2019, , .		0
45	Supplementing Claims Data with Electronic Medical Records to Improve Estimation and Classification of Rheumatoid Arthritis Disease Activity: A Machine Learning Approach. <i>ACR Open Rheumatology</i> , 2019, 1, 552-559.	2.1	7
46	The Impact of Exercise, Lifestyle, and Clinical Factors on Perceived Cognitive Function in Patients with Rheumatoid Arthritis: Results from a Prospective Cohort Study. <i>ACR Open Rheumatology</i> , 2019, 1, 620-626.	2.1	9
47	Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 874-883.	1.9	16
48	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 872-878.	0.9	36
49	Impact of Changes in Inflammation on Estimated Tenâ€¢Year Cardiovascular Risk in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1392-1398.	5.6	13
50	Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1419-1428.	5.6	21
51	Association of Low Bone Mineral Density with Anti-Citrullinated Protein Antibody Positivity and Disease Activity in Established Rheumatoid Arthritis: Findings from a US Observational Cohort. <i>Advances in Therapy</i> , 2018, 35, 232-242.	2.9	9
52	Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis. <i>Rheumatology and Therapy</i> , 2018, 5, 203-214.	2.3	10
53	Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 832-840.	5.6	103
54	Mavrimumab, a Fully Human Granulocyteâ€¢Macrophage Colonyâ€¢Stimulating Factor Receptor Î± Monoclonal Antibody. <i>Arthritis and Rheumatology</i> , 2018, 70, 679-689.	5.6	73

#	ARTICLE	IF	CITATIONS
55	Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids. <i>Arthritis and Rheumatology</i> , 2018, 70, 1331-1342.	5.6	15
56	Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e4-e4.	0.9	7
57	Phase <sc>III</sc> Randomized Study of <sc>SB</sc>5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 40-48.	5.6	104
58	A Randomized Phase <sc>II</sc>b Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 49-59.	5.6	76
59	221â€fDevelopment of abatacept- and adalimumab-specific predictive models of response to therapy in rheumatoid arthritis using data from a head-to-head study. <i>Rheumatology</i> , 2018, 57, .	1.9	0
60	Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0205013.	2.5	9
61	Phase <sc>II</sc> Study of <sc>ABT</sc>â€122, a Tumor Necrosis Factorâ€ and Interleukinâ€17Aâ€Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate. <i>Arthritis and Rheumatology</i> , 2018, 70, 1778-1789.	5.6	77
62	<sc>ABT</sc>â€122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukinâ€17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate. <i>Arthritis and Rheumatology</i> , 2018, 70, 1710-1720.	5.6	55
63	Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. <i>Rheumatology</i> , 2018, 57, 1972-1981.	1.9	30
64	Methotrexate: who would have predicted its importance in rheumatoid arthritis?. <i>Arthritis Research and Therapy</i> , 2018, 20, 103.	3.5	18
65	Targeted therapies for psoriatic arthritis: an update for the dermatologist. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018, 37, 173-181.	1.6	4
66	Serum Proteomics Reveals Distinct Subtypes Associated with Treatment Response in Idiopathic Multicentric Castleman Disease. <i>Blood</i> , 2018, 132, 3716-3716.	1.4	0
67	Diet and Rheumatoid Arthritis Symptoms: Survey Results From a Rheumatoid Arthritis Registry. <i>Arthritis Care and Research</i> , 2017, 69, 1920-1925.	3.4	49
68	A randomised phase IIb study of mavrilimumab, a novel GMâ€CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1020-1030.	0.9	117
69	Fibromyalgia and the Prediction of Twoâ€Year Changes in Functional Status in Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2017, 69, 1871-1877.	3.4	12
70	Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2017, 376, 652-662.	27.0	643
71	Antimelanoma Differentiation-associated Gene 5 Dermatomyositis. <i>Journal of Rheumatology</i> , 2017, 44, 850-851.	2.0	2
72	Refractory Syndrome of Inappropriate Secretion of Antidiuretic Hormone in Systemic Lupus Erythematosusâ€associated Hypophysitis. <i>Journal of Rheumatology</i> , 2017, 44, 541-542.	2.0	3

#	ARTICLE	IF	CITATIONS
73	Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1853-1861.	0.9	83
74	Clinical patient registry recruitment and retention: a survey of patients in two chronic disease registries. <i>BMC Medical Research Methodology</i> , 2017, 17, 59.	3.1	7
75	Validity of the Nursesâ€™ health study physical activity questionnaire in estimating physical activity in adults with rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 234.	1.9	9
76	Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement. <i>Arthritis Research and Therapy</i> , 2017, 19, 130.	3.5	2
77	A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1937-1948.	5.6	32
78	Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities. <i>Arthritis and Rheumatology</i> , 2017, 69, 720-727.	5.6	24
79	Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration. <i>RMD Open</i> , 2016, 2, e000210.	3.8	3
80	Patientâ€™Reported Outcomes From a Twoâ€™Year Headâ€™toâ€™Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 907-913.	3.4	24
81	Efficacy and Safety of ABTâ€™494, a Selective JAKâ€™1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. <i>Arthritis and Rheumatology</i> , 2016, 68, 2857-2866.	5.6	172
82	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. <i>Nature Communications</i> , 2016, 7, 12460.	12.8	73
83	Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia. <i>Rheumatology</i> , 2016, 55, 640-648.	1.9	29
84	Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 709-714.	0.9	134
85	Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Weekâ€™12 Efficacy and Safety Results of the Openâ€™Label Longâ€™Term Extension of a Phase III, Doubleâ€™Blind, Randomized, Placeboâ€™Controlled Trial. <i>Arthritis Care and Research</i> , 2015, 67, 1627-1636.	3.4	13
86	Editorial: The Vital Role of Randomized Controlled Trials in <i>Arthritis & Rheumatology</i>. <i>Arthritis and Rheumatology</i> , 2015, 67, 2555-2556.	5.6	1
87	Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. <i>Arthritis Research and Therapy</i> , 2015, 17, 325.	3.5	16
88	Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity. <i>Arthritis Research and Therapy</i> , 2015, 17, 343.	3.5	13
89	The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderateâ€™Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Doubleâ€™Blind, Placebo/Activeâ€™Controlled, Doseâ€™Ranging Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 2591-2600.	5.6	86
90	The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. <i>Rheumatology</i> , 2015, 54, 2076-2084.	1.9	74



#	ARTICLE	IF	CITATIONS
91	The Association Between Reduction in Inflammation and Changes in Lipoprotein Levels and HDL Cholesterol Efflux Capacity in Rheumatoid Arthritis. Journal of the American Heart Association, 2015, 4, .	3.7	102
92	OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. Annals of the Rheumatic Diseases, 2015, 74, 2123-2129.	0.9	39
93	Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. Seminars in Arthritis and Rheumatism, 2015, 45, 167-173.	3.4	58
94	Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. Annals of the Rheumatic Diseases, 2015, 74, 1567-1570.	0.9	31
95	An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score. Arthritis Research and Therapy, 2015, 17, 83.	3.5	13
96	Modular Analysis of Peripheral Blood Gene Expression in Rheumatoid Arthritis Captures Reproducible Gene Expression Changes in Tumor Necrosis Factor Responders. Arthritis and Rheumatology, 2015, 67, 344-351.	5.6	42
97	Clinical characteristics of RA patients with secondary SS and association with joint damage. Rheumatology, 2015, 54, 816-820.	1.9	41
98	Functional Impact of a Spectrum of Interstitial Lung Abnormalities in Rheumatoid Arthritis. Chest, 2014, 146, 41-50.	0.8	78
99	Inconsistent Treatment with Disease-modifying Antirheumatic Drugs: A Longitudinal Data Analysis. Journal of Rheumatology, 2014, 41, 2370-2378.	2.0	9
100	Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1â€¦year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial. Annals of the Rheumatic Diseases, 2014, 73, 2152-2159.	0.9	29
101	Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. Arthritis and Rheumatology, 2014, 66, 3255-3264.	5.6	96
102	Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept) Tj ETQq0 0 0 rgBT /Overlock 10 Tf therapy. Annals of the Rheumatic Diseases, 2014, 73, 1616-1625.	0.9	135
103	The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure) Tj ETQq1 1 0.784314 rgBT /Overlock	1.7	14
104	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: Table A1. Annals of the Rheumatic Diseases, 2014, 73, 1755-1760.	0.9	11
105	The Effect of Intravenous Golimumab on Health-related Quality of Life in Rheumatoid Arthritis: 24-week Results of the Phase III GO-FURTHER Trial. Journal of Rheumatology, 2014, 41, 1067-1076.	2.0	14
106	A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-Î± Antagonist. Journal of Rheumatology, 2014, 41, 2120-2128.	2.0	57
107	Serum 14-3-3Î³ is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2014, 41, 2104-2113.	2.0	72
108	Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Annals of the Rheumatic Diseases, 2014, 73, 86-94.	0.9	256

#	ARTICLE	IF	CITATIONS
109	Rheumatoid arthritis quality measures and radiographic progression. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 9-13.	3.4	6
110	86.â€fHead-to-Head Comparison of Subcutaneous Abatacept Versus Adalimumab on Background Methotrexate in Rheumatoid Arthritis: Blinded Two-Year Results from the Ample Study. <i>Rheumatology</i> , 2014, 53, i88-i88.	1.9	0
111	Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1445-1452.	0.9	149
112	Headâ€toâ€head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. <i>Arthritis and Rheumatism</i> , 2013, 65, 28-38.	6.7	225
113	Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program. <i>Journal of Rheumatology</i> , 2013, 40, 787-797.	2.0	112
114	Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 381-389.	0.9	90
115	Tocilizumab as monotherapy or in combination with nonbiologic diseaseâ€modifying antirheumatic drugs: Twentyâ€fourâ€week results of an openâ€label, clinical practice study. <i>Arthritis Care and Research</i> , 2013, 65, 362-371.	3.4	56
116	Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial. <i>Journal of Rheumatology</i> , 2013, 40, 369-378.	2.0	42
117	Methotrexate in rheumatoid arthritis: a quarter century of development. <i>Transactions of the American Clinical and Climatological Association</i> , 2013, 124, 16-25.	0.5	117
118	Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. <i>Rheumatology</i> , 2012, 51, 2204-2214.	1.9	115
119	Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2011, 63, 373-382.	3.4	58
120	A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 846-854.	2.0	108
121	An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A threeâ€month randomized, placeboâ€controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. <i>Arthritis and Rheumatism</i> , 2011, 63, 337-345.	6.7	190
122	Clinical Consequences of Delayed Addition of Adalimumab to Methotrexate Therapy Over 5 Years in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 855-862.	2.0	25
123	Factors Associated with Radiographic Progression in Patients with Rheumatoid Arthritis Who Were Treated with Methotrexate. <i>Journal of Rheumatology</i> , 2011, 38, 242-246.	2.0	23
124	An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2010, 363, 1303-1312.	27.0	369
125	Case 13-2009. <i>New England Journal of Medicine</i> , 2009, 360, 1770-1779.	27.0	9
126	Methotrexate: The Foundation of Rheumatoid Arthritis Therapy. , 2009, , 307-314.		1



#	ARTICLE	IF	CITATIONS
127	Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double-blind, active drug-controlled study. <i>Arthritis and Rheumatism</i> , 2008, 58, 1921-1930.	6.7	71
128	Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2008, 58, 3309-3318.	6.7	313
129	Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. <i>Arthritis Research and Therapy</i> , 2008, 10, R95.	3.5	57
130	Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 1737-44.	2.0	27
131	Questions and answers in 2008 about biologics in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 1878-81.	2.0	0
132	RAPID: rheumatoid arthritis. <i>Journal of Family Practice</i> , 2007, 56, S1-7; quiz S8.	0.2	6
133	The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28. <i>Arthritis Research and Therapy</i> , 2006, 8, R57.	3.5	22
134	Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 228-234.	0.9	261
135	Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. <i>Journal of Rheumatology</i> , 2006, 33, 659-64.	2.0	34
136	Granulomatous lung disease occurring during etanercept treatment. <i>Arthritis and Rheumatism</i> , 2005, 53, 618-620.	6.7	70
137	Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. <i>Arthritis and Rheumatism</i> , 2005, 53, 872-878.	6.7	49
138	Rheumatoid arthritis: more aggressive approach improves outlook.. <i>Cleveland Clinic Journal of Medicine</i> , 2004, 71, 409-413.	1.3	14
139	Adalimumab, a fully human anti-tumor necrosis factor $\gamma$ monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. <i>Arthritis and Rheumatism</i> , 2003, 48, 35-45.	6.7	1,612
140	Infections and anti-tumor necrosis factor $\gamma$ therapy. <i>Arthritis and Rheumatism</i> , 2003, 48, 3013-3022.	6.7	285
141	The best of times, the worst of times: <i>Rheumatology</i> 2001. <i>Arthritis and Rheumatism</i> , 2002, 46, 567-573.	6.7	9
142	How to report radiographic data in randomized clinical trials in rheumatoid arthritis: Guidelines from a roundtable discussion. <i>Arthritis and Rheumatism</i> , 2002, 47, 215-218.	6.7	132
143	Etanercept in the treatment of adult patients with Still's disease. <i>Arthritis and Rheumatism</i> , 2002, 46, 1171-1176.	6.7	179
144	Serious liver disease in a patient receiving methotrexate and leflunomide. <i>Arthritis and Rheumatism</i> , 2000, 43, 2609-2611.	6.7	46

#	ARTICLE	IF	CITATIONS
145	Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1999, 42, 1322-1328.	6.7	248
146	A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate. <i>New England Journal of Medicine</i> , 1999, 340, 253-259.	27.0	2,044
147	Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis. A multicenter study with literature review. <i>Arthritis and Rheumatism</i> , 1997, 40, 1829-1837.	6.7	279
148	Evaluation of two interventions to reduce the ancillary costs of outpatient care for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1996, 39, 177-178.	6.7	3
149	N-[4-hydroxyphenyl] retinamide in rheumatoid arthritis: A pilot study. <i>Arthritis and Rheumatism</i> , 1996, 39, 1021-1026.	6.7	15
150	Synovial tissue response to treatment with campath-1h. <i>Arthritis and Rheumatism</i> , 1995, 38, 254-258.	6.7	50
151	American college of rheumatology preliminary definition of improvement in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995, 38, 727-735.	6.7	2,531
152	Methotrexate for Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 1994, 37, 316-328.	6.7	594
153	Lack of a renalâ€“protective effect of misoprostol in rheumatoid arthritis patients receiving cyclosporin a. results of a randomized, placeboâ€“controlled trial. <i>Arthritis and Rheumatism</i> , 1994, 37, 1321-1325.	6.7	8
154	Methotrexate in rheumatoid arthritis. a five-year prospective multicenter study. <i>Arthritis and Rheumatism</i> , 1994, 37, 1492-1498.	6.7	216
155	Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1993, 36, 329-335.	6.7	187
156	The effects of drug therapy on radiographic progression of rheumatoid arthritis. results of a 36-week randomized trial comparing methotrexate and auranofin. <i>Arthritis and Rheumatism</i> , 1993, 36, 613-619.	6.7	100
157	The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. <i>Arthritis and Rheumatism</i> , 1993, 36, 729-740.	6.7	1,388
158	Long-Term Prospective Study of Methotrexate in the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 1992, 35, 129-137.	6.7	227
159	Acute and chronic suppression of leukotriene B <sub>4</sub> synthesis EX vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. <i>Arthritis and Rheumatism</i> , 1992, 35, 376-384.	6.7	99
160	Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1990, 33, 330-338.	6.7	126
161	Inhibition of Leukotriene B <sub>4</sub> synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. <i>Arthritis and Rheumatism</i> , 1990, 33, 1149-1155.	6.7	63
162	Treatment of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1989, 2, A23-A32.	6.7	11

#	ARTICLE	IF	CITATIONS
163	Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis and Rheumatism, 1989, 32, 1592-1596.	6.7	85
164	Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis and Rheumatism, 1988, 31, 167-175.	6.7	235
165	Cyclosporin A Treatment of Refractory Rheumatoid Arthritis. Arthritis and Rheumatism, 1987, 30, 11-17.	6.7	134
166	Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis. Arthritis and Rheumatism, 1987, 30, 988-997.	6.7	207
167	Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis. Clinical Pharmacology and Therapeutics, 1986, 39, 420-424.	4.7	7
168	Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis. New England Journal of Medicine, 1985, 312, 818-822.	27.0	833
169	Chronic Monocytic Arthritis. Arthritis and Rheumatism, 1983, 26, 674-677.	6.7	3
170	Rheumatoid factor detection by nephelometry. Arthritis and Rheumatism, 1980, 23, 777-779.	6.7	21